SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

被引：15

作者：

Baselga, J. ^{[1
]}

Segalla, J. G. M. ^{[2
]}

Roche, H. ^{[3
]}

del Giglio, A. ^{[4
]}

Ciruelos, E. M. ^{[5
]}

Cabral Filho, S. ^{[6
]}

Gomez, P. ^{[1
]}

Lluch, A. ^{[7
]}

Llombart, A. ^{[8
]}

Costa, F. ^{[9
]}

机构：

[1] Vall Hebron Univ Hosp, VHIO, Barcelona, Spain

[2] Fundacao Dr Amaral Carvalho Hematol & Oncol, Jau, Brazil

[3] Inst Claudius Regaud, Toulouse, France

[4] ABC CEPHO, Hematol & Oncol, Santo Andre, Brazil

[5] Hosp Univ 12 Octubre, Madrid, Spain

[6] Clin Santa Casa Belo Horizonte, Belo Horizonte, MG, Brazil

[7] Hosp Clin Univ Valencia, Valencia, Spain

[8] Hosp Univ Arnau de Vilanova Lleida, Lleida, Spain

[9] IBPC, Sao Paulo, Brazil

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 03期

关键词：

D O I：

10.1016/S1359-6349(09)72031-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 4

页数：2